Results 41 to 50 of about 740 (167)
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Cancer Management and Research, 2022 Yumeng Zhang,1,2 Lubomir Sokol2 1Department of Internal Medicine, University of South Florida, Tampa, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USACorrespondence: Yumeng Zhang; Lubomir Sokol, Email yumeng.zhang ...
Zhang Y, Sokol L
doaj
Hematology, Transfusion and Cell Therapy, 2023 Introdução/Objetivos: A NCDPB é uma doença rara, com comportamento agressivo e prognóstico sombrio, perfazendo menos de 0,5% de todas as neoplasias hematológicas. O trabalho visa expor o relato de caso sobre a mesma, com os desafios e limitações impostas
JPS Siqueira +9 more
doaj +1 more source
CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
, 2022 SIMPLE SUMMARY: Until recently, there were no approved therapies for the aggressive blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN). Survival for patients diagnosed with BPDCN is under two years, and improved treatments are needed.
Naveen Pemmaraju +9 more
core +1 more source
Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp. [PDF]
J Adv Pract OncolBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, orphan hematologic malignancy that expresses CD123 and frequently presents in skin, bone marrow, blood, and viscera. Tagraxofusp is a first-in-class CD123-targeted therapy and the only US-approved drug to treat BPDCN.
Faysman K +7 more
europepmc +3 more sources
Blast and Bursts: Unveiling Splenic Rupture in Blastic Plasmacytoid Dendritic Cell Neoplasia. [PDF]
J Community Hosp Intern Med PerspectBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic cancer, accounting for less than 1% of acute leukemias in the U.S. Diagnosis involves detecting markers like CD123, CD4, CD56, TCL1, and TCF4.
Hassan A +6 more
europepmc +2 more sources
, 2020 International audienceBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes.
Beziat, Guillaume, Ysebaert, Loïc
core +1 more source
Frontiers in Oncology, 2021 Cancer is one of the prominent causes of death worldwide. Despite the existence of various modalities for cancer treatment, many types of cancer remain uncured or develop resistance to therapeutic strategies.
Seyed Mehdi Havaei +2 more
doaj +1 more source
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Rash
, 2023 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy derived from type 2 Dendritic cells (immature Plasmacytoid dendritic cells).
Charmee Vyas +9 more
core +1 more source
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Journal of Clinical Oncology, 2022 Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or ...
Naveen Pemmaraju +12 more
openaire +2 more sources
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm
Therapeutic Advances in Hematology, 2019 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides +2 more
doaj +1 more source